Model Informed Drug Development Archives

Publication

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…

CertaraJanuary 22, 2026

On-Demand Webinar

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

Watch this on-demand webinar to learn how model-based meta-analysis (MBMA), quantitative systems pharmacology (QSP), and…

CertaraJanuary 22, 2026

Webinar

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

CertaraJanuary 14, 2026

On-Demand Webinar

Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies

Watch this on-demand webinar featuring former regulators as they share global regulatory trends and clinical…

CertaraJanuary 14, 2026

On-Demand Webinar

Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data

Learn how to interpret screening assay data to predict clinical off-target risk with ToxStudio® and…

CertaraJanuary 13, 2026

Publication

Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development

Quantitative Systems Pharmacology (QSP) and Pharmacometrics (PMX) have historically existed at the two ends of…

CertaraJanuary 7, 2026

Blog

Delivering on Deadline: Why Pharmacometrics (PMx) Is the Anchor of Successful Regulatory Submissions

Explore how PMx regulatory submissions, exposure-response modeling, and strategic pharmacometrics planning support successful and timely…

CertaraDecember 29, 2025

Fact Sheet

Strategic Project Management for Accelerated Drug Development

Expert project leadership to keep complex programs on track, aligned, and moving forward—so you can…

CertaraDecember 23, 2025

Conference

MVA Oncology Network

CertaraDecember 19, 2025

Publication

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection

This study synthesizes data from a large body of clinical trials to evaluate rates of…

CertaraDecember 18, 2025

Model Informed Drug Development

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies

Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data

Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development

Delivering on Deadline: Why Pharmacometrics (PMx) Is the Anchor of Successful Regulatory Submissions

Strategic Project Management for Accelerated Drug Development

MVA Oncology Network

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection

Newsletter sign up

Quick links

Solutions

Contact